Banff 2011 Meeting report: new concepts in antibody-mediated rejection - Wikidata - wikimedia - TriplyDB

Banff 2011 Meeting report: new concepts in antibody-mediated rejection

Banff 2011 Meeting report: new concepts in antibody-mediated rejection

http://www.wikidata.org/entity/Q37058043

about

Translational research in kidney transplantation and the role of patient engagement Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation What is the best way to measure renal fibrosis?: A pathologist’s perspective Transplantation tolerance and its outcome during infections and inflammation Direct and Indirect Effects of Cytomegalovirus-Induced γδ T Cells after Kidney Transplantation MHC class I signaling: new functional perspectives for an old molecule The importance of C4d in biopsies of kidney transplant recipients Effector mechanisms of rejection Monocyte recruitment by HLA IgG-activated endothelium: the relationship between IgG subclass and FcγRIIa polymorphisms.Banff Initiative for Quality Assurance in Transplantation (BIFQUIT): reproducibility of polyomavirus immunohistochemistry in kidney allografts.Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy.Clinical aspects: focusing on key unique organ-specific issues of renal transplantation.Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy.Eculizumab in Transplant-Associated Thrombotic Microangiopathy.Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial Use of bortezomib as anti-humoral therapy in kidney transplantation.Immunologic human renal allograft injury associates with an altered IL-10/TNF-α expression ratio in regulatory B cells.Neutralizing BAFF/APRIL with atacicept prevents early DSA formation and AMR development in T cell depletion induced nonhuman primate AMR model.Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection.Cytomegalovirus-responsive γδ T cells: novel effector cells in antibody-mediated kidney allograft microcirculation lesions.Diagnosis and management of antibody-mediated rejection: current status and novel approaches.Characterization of transfusion-elicited acute antibody-mediated rejection in a rat model of kidney transplantation.A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation.Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss.Quantification of C4d deposition and hepatitis C virus RNA in tissue in cases of graft rejection and hepatitis C recurrence after liver transplantation.Acute liver allograft antibody-mediated rejection: an inter-institutional study of significant histopathological features.Endothelial cell antibodies associated with novel targets and increased rejection.Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts.Outcome after Desensitization in HLA or ABO-Incompatible Kidney Transplant Recipients: A Single Center Experience.Capillary C4d and Kidney Allograft Outcome in Relation to Morphologic Lesions Suggestive of Antibody-Mediated Rejection Renal interstitial fibrosis: mechanisms and evaluation.CD28 family and chronic rejection: "to belatacept...And beyond!".IL-34 mediates acute kidney injury and worsens subsequent chronic kidney disease.Decreased Kidney Graft Survival in Low Immunological Risk Patients Showing Inflammation in Normal Protocol Biopsies.Rational clinical trial design for antibody mediated renal allograft injury.Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation.Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients.B Cells, Antibodies, and More.Long-term Renal Function in Living Kidney Donors Who Had Histological Abnormalities at Donation

P2860

Q26778752-BBEE4779-ED59-4B99-9E1D-C969186B6FAD Q26780271-E1EAEB19-448A-4FC2-BC6F-AC6AA041BDD1 Q26796641-8C164753-BA75-46B7-9AFC-08CFCF5365CE Q26829817-6ACE2023-AA6E-4335-851B-1414D4EE20D4 Q26863724-91F06C9C-059F-49D9-A169-92DB621FEC6F Q27000194-7C33E985-0402-45F4-9F2C-BE9AB0B80D3E Q27021227-92F255FB-D5FA-4563-B8E6-93AA3E232D83 Q27027082-F384A622-73D9-45E2-923E-8018E73C8079 Q27314948-ABA08376-6CA7-4347-A562-B095FE6BF6AD Q30371017-568A1A00-3ADA-4CCC-BA3E-6340299C03D7 Q33407913-2803E0B6-F731-464D-BC3C-8164FFBA1A2B Q33412327-6B5A9891-E2E4-436B-BB08-03964913E182 Q33424902-980461D6-32B5-4081-A193-1A3E4F4977C6 Q33425079-EABF8DEF-2F73-4214-B5B3-32E596CB0652 Q33584895-0CBA35E2-21E1-4D7C-BC86-DA354D791AE8 Q33627580-08F55A17-CCB1-4193-B392-6AAE3F741691 Q33814904-FBD695DC-89CF-4435-B92C-B5115A82632B Q33891669-12CCF294-F953-4B66-AB08-35D6E92717FA Q34260097-DF425BA3-0A84-4184-93C5-A6ECDBCA3547 Q34427661-2642B747-F68F-49BA-B995-537A9D679AE5 Q34841849-1723D852-11C0-4467-9BC6-6374D51EC4D7 Q34901573-5BF986B3-41AF-4AB6-A398-7B08E19019B0 Q35008036-D892A521-C2D2-4A05-A29D-FEA9941F3DF7 Q35027253-1F26B78D-EECA-441C-A0A1-BBDCC9E3D7CE Q35210857-BB6016FD-4AF6-411C-A04E-06AAEE5EF01A Q35546323-0C99E041-DE90-45B4-A075-5190EF0BA677 Q35550551-C35BFC5C-DC5B-4765-A1B5-23E75943D51C Q35790552-3B0B09C4-D06E-43CA-8B5B-2E5BF0766E4A Q35885244-34BEAFF4-F0A0-4B46-A1B3-27CBF6633A36 Q35922715-9FF76A9F-1714-4B6B-B8EF-2CFA78EF86CD Q35967489-54A8E77D-657C-4369-A1B2-6204F81C4ECF Q36037639-E71D273B-5E4C-48EC-9CD3-7C8DAA14612C Q36040523-A981B01B-004A-470A-A9F9-3408AE50EB4E Q36105785-4894E380-43B6-4A65-A628-D94D3C05B9EE Q36173541-FF278ABD-C456-44F0-BDD2-4B1E115B6EEE Q36216606-BE9BFA02-484A-4125-9E21-F75FC63C1075 Q36240178-88C3C8AF-B494-447A-8655-30CC3CB3BE4F Q36296061-953C85A6-7937-4F21-B530-CBCA5AB891AE Q36432935-2B0A430A-A9EF-4BDE-A1D6-72755B265778 Q36765021-0EEEB9FC-E91B-4788-85E6-66C1F4098B56

P2860

Banff 2011 Meeting report: new concepts in antibody-mediated rejection

http://www.wikidata.org/entity/Q37058043

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 February 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Banff 2011 Meeting report: new concepts in antibody-mediated rejection

@en

Banff 2011 Meeting report: new concepts in antibody-mediated rejection.

@nl

type

label

Banff 2011 Meeting report: new concepts in antibody-mediated rejection

@en

Banff 2011 Meeting report: new concepts in antibody-mediated rejection.

@nl

prefLabel

Banff 2011 Meeting report: new concepts in antibody-mediated rejection

@en

Banff 2011 Meeting report: new concepts in antibody-mediated rejection.

@nl

P1433

Q37058043-41786C4B-C8DE-4B74-9333-300D6389F60F

P1476

Q37058043-A451B3DB-8AFB-401A-9DAD-D795B33726D1

P2093

Q37058043-08CA3A89-85FF-49BA-BDC8-E27F37142AF6

Q37058043-115B15D6-C602-45CD-841D-279043CE156A

Q37058043-12A54630-7E17-4836-A2AB-211366D499EF

Q37058043-208C7205-5D0C-4890-97E4-67DEB49142CF

Q37058043-224050AC-046F-46D0-B126-E7280CA39BF4

Q37058043-257F8A74-9ABE-4C2A-BDB1-63FEE4931E47

Q37058043-2CEF0854-0624-4791-BCB0-CBC637ACA567

Q37058043-53C929FB-6D45-463B-A03C-2649CE29C6B2

Q37058043-56FC9D62-AF64-4847-9D0F-5D71A34995AD

Q37058043-8EF7FA1C-7311-4D99-BCD7-48B8B94C8290

P2860

Q37058043-0127E383-71E6-4D9A-9A3E-51EC23F2071F

Q37058043-01E3BF72-D6F5-47E2-9555-036DAEFF1269

Q37058043-093A18B6-1B09-47FD-83F2-4B71DB778472

Q37058043-1ECBDB9D-E382-461C-8B97-768127A17B9F

Q37058043-2142D337-845F-47BC-82F2-3C1AB6F841A9

Q37058043-216B4E7D-1725-4643-B16D-0F4ED7662432

Q37058043-321C94C0-2F4D-4426-B3C2-2849FFC42B8A

Q37058043-3B068A14-90AD-4015-AAAC-55D99F0DFA12

Q37058043-3E6406AD-D2DF-407A-9370-AEF2547629B6

Q37058043-445663CE-B5C0-4356-A605-C9A3C496D839

P304

Q37058043-A418CB9F-4820-4ADD-9ABC-B6C463B8D496

P31

Q37058043-99FA3113-CDF2-4BAC-A13D-5B0CE0DA7BC4

P356

Q37058043-6FE03B58-3B9A-46BC-B7C2-F42AFEDEDB62

P407

Q37058043-5C2CFCC9-CE82-4CDA-AF09-A444BC3D9B52

P433

Q37058043-034AC407-46B1-47F0-BC48-134C9B37F613

P478

Q37058043-5A7DB189-E739-4128-9246-0B1F56E44254

P50

Q37058043-5191A3F4-868A-4EE4-A788-914D2C55CEEB

P577

Q37058043-AC2170CF-1F06-428A-8B14-4A84E754E78A

P5875

Q37058043-F43C88A2-3995-4ED3-AB2E-D15D30AA6ABE

P698

Q37058043-4FE61E1F-15C4-4CEA-BBF2-39DDA36A1189

P921

Q37058043-03D1D552-0E8D-42BF-91D8-56C2CAB44F96

P932

Q37058043-56DA1B73-65D3-427D-9ECF-AA0B39D26355

P356

J.1600-6143.2011.03926.X

P1433

American Journal of Transplantation

P1476

Banff 2011 Meeting report: new concepts in antibody-mediated rejection

@en

P2093

B Sis

http://www.w3.org/2001/XMLSchema#string

Banff meeting report writing committee

http://www.w3.org/2001/XMLSchema#string

C B Drachenberg

http://www.w3.org/2001/XMLSchema#string

C F Farver

http://www.w3.org/2001/XMLSchema#string

D Glotz

http://www.w3.org/2001/XMLSchema#string

E R Rodriguez

http://www.w3.org/2001/XMLSchema#string

K Solez

http://www.w3.org/2001/XMLSchema#string

L C Racusen

http://www.w3.org/2001/XMLSchema#string

L Cendales

http://www.w3.org/2001/XMLSchema#string

M Haas

http://www.w3.org/2001/XMLSchema#string

P2860

Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy.

Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation

Fibrosis with inflammation at one year predicts transplant functional decline.

Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients.

Transplant glomerulopathy.

The Banff 2007 working classification of skin-containing composite tissue allograft pathology.

Focal C4d+ in renal allografts is associated with the presence of donor-specific antibodies and decreased allograft survival.

Sensitized renal transplant recipients: current protocols and future directions.

The evolution and clinical impact of human leukocyte antigen technology.

The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: evolution and current status (2005-2011).

P304

563-570

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1600-6143.2011.03926.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Anthony J. Demetris

P577

2012-02-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221801354

http://www.w3.org/2001/XMLSchema#string

P698

22300494

http://www.w3.org/2001/XMLSchema#string

P921

P932

3728651

http://www.w3.org/2001/XMLSchema#string